Correction to: European Journal of Pediatrics (2022) 182:757–767
https://doi.org/10.1007/s00431-022-04674-7
In the original published version of the above article, the data reported with ‘yes’ and ‘no’ under "Child migration background" are switched up. The Table 1 below is the correct listing.
Table 1
Participant characteristics
All (n = 105) | Propranolol (n = 36) | Atenolol (n = 69) | p-value | |
|---|---|---|---|---|
Demographics | ||||
Child age, years | ||||
Median (IQR) | 7.4 (6.7–8.5) | 8.0 (7.3–8.8) | 7.1 (6.4–8.1) | < 0.001 |
Range | 6.0–11.8 | 6.4–11.8 | 6.0–9.7 | |
Child sex, n (%) | ||||
Female | 85 (81) | 29 (81) | 56 (81) | > 0.99 |
Male | 20 (19) | 7 (19) | 13 (19) | |
Child migration backgrounda, n (%) | ||||
Yes | 10 (10) | 0 (0.0) | 10 (14) | 0.01 |
No | 94 (90) | 36 (100) | 58 (84) | |
Unknown | 1 (1.0) | 0 (0.0) | 1 (1.4) | |
Education mother, n (%) | ||||
Low | 14 (13) | 6 (17) | 8 (12) | 0.89 |
Average | 28 (27) | 8 (22) | 20 (29) | |
High | 62 (59) | 22 (61) | 40 (58) | |
Unknown | 1 (1.0) | 0 (0.0) | 1 (1.4) | |
Home language, n (%) | ||||
Dutch | 97 (92) | 35 (97) | 62 (90) | 0.37 |
Other | 2 (2.0) | 0 (0.0) | 2 (2.9) | |
Multilingual | 6 (5.7) | 1 (2.8) | 5 (7.2) | |
Confirmed diagnosis, n (%) | ||||
Attention deficit/hyperactivity disorder | 6 (5.7) | 3 (8.3) | 3 (4.3) | |
Clinical information | ||||
Location of IHb, n (%) | ||||
Head and neck | 84 (80) | 24 (67) | 60 (87) | 0.02 |
Trunk | 13 (12) | 6 (17) | 7 (10) | 0.36 |
Genital area | 13 (12) | 7 (19) | 6 (8.7) | 0.13 |
Extremities | 7 (6.7) | 3 (8.3) | 4 (5.8) | 0.69 |
Ulcerated IH, n (%) | ||||
Yes | 29 (28) | 13 (36) | 16 (23) | 0.16 |
No | 76 (72) | 23 (64) | 53 (77) | |
Treatment center, n (%) | ||||
Erasmus MC | 34 (32) | 31 (86) | 3 (4.3) | < 0.001 |
UMCU | 71 (68) | 5 (14) | 66 (96) | |
Age at treatment initiation, months | ||||
Median (IQR) | 3.5 (2.2–5.1) | 3.6 (2.2–5.3) | 3.4 (2.2–5.0) | 0.58 |
Range | 0.92–11.4 | 1.64–11.4 | 0.92–10.9 | |
Treatment duration, months | ||||
Median (IQR) | 13.8 (10.9–19.4) | 18.6 (12.5–22.7) | 13.0 (10.4–15.8) | 0.001 |
Range | 6.41–62.7 | 9.13–62.7 | 6.41–56.8 | |
Average dose, mg/kg/day | ||||
Median (IQR) | 1.2 (1.0–1.8) | 1.9 (1.8–2.0) | 1.0 (1.0–1.2) | < 0.001 |
Range | 0.8–2.5 | 1.4–2.5 | 0.8–2.0 | |
Peak dose, mg/kg/day | ||||
Median (IQR) | 1.6 (1.0–2.1) | 2.1 (2.0–2.3) | 1.0 (1.0–1.6) | < 0.001 |
Range | 1.0–14.0 | 1.9–14.0 | 1.0–3.0 | |
Cumulative dose, mg/kg | ||||
Median (IQR) | 577.4 (387.2–881.7) | 1122.7 (718.6–1282.3) | 418.7 (310.0–619.7) | < 0.001 |
Range | 186.6–3544 | 494.1–3544 | 186.6–2206 | |
Follow-up timec, years | ||||
Median (IQR) | 5.9 (5.2–6.5) | 6.2 (5.6–6.6) | 5.7 (5.1–6.2) | 0.13 |
Range | 1.6–9.7 | 1.6–9.7 | 4.5–8.4 | |
Anzeige
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.